Beni-Suef University

bsu.edu.eg

Total trials

291

Active

66

Phase 3

38

Total enrollment

66,869

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 40 of 47 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ventoline® Evohaler® 100 µg/inhalation pMDI alone1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package1
Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer1
Clindamycin vaginal cream1
Vaginal preparation with povidone- iodide solution 10 %1
Colistimethate Sodium1
Tigecycline1
Tadalafil 5mg1
estradiol valerate 2 mg1
diosmin/hesperdin1
Myoinositol2
Letrozole 2.5mg3
Metformin3
Dapagliflozin/Metformin2
Probiotic Formula1
Control1
pentoxifylline 400 mg1
Co-Enzyme Q101
Melatonin1
Folic acid1
Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.1
DHEA plus folic acid 400mcg per day1
Inhaled nitroglycerin1
Dapagliflozin1
Letrozole1
Chromium1
l-arginine1
Control group3
Conventional pharmacological therapy1
tadalafil 20 mg then 40 mg if tolerated1
GLP-1 analog1
SGLT2 inhibitor1
Antidiabetic1
7 more active programs hidden

Next readouts

  • 2024-12-30
  • 2024-12-30
  • 2024-12-31
  • 2025-02-10
  • 2025-04-26
  • 2025-05-30
  • 2025-10-01
  • 2025-12-30
  • 2026-01-28
  • 2026-02-15

Top conditions

  • IVF8
  • Pain5
  • Breast Cancer5
  • Chronic Hepatitis C Virus Infection4
  • Patient Satisfaction3
  • Educational Problems3
  • Covid193
  • Cerebral Palsy3

Frequently asked questions about Beni-Suef University

How many clinical trials does Beni-Suef University have on ClinicalTrials.gov?
Beni-Suef University is listed as the lead sponsor on 291 clinical trials in ClinicalTrials.gov, 66 of which are currently active (recruiting, enrolling, or ongoing).
How many of Beni-Suef University's trials are in Phase 3?
38 of Beni-Suef University's trials are in Phase 3, spread across 47 active drug programs.
What therapeutic areas does Beni-Suef University focus on?
Beni-Suef University's most-studied conditions on ClinicalTrials.gov are IVF, Pain, Breast Cancer, Chronic Hepatitis C Virus Infection, Patient Satisfaction.
When are Beni-Suef University's next clinical trial readouts?
Beni-Suef University has 10 upcoming primary-completion readouts tracked here; the soonest is “of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve”, expected around 2024-12-30.